NCT01595685View on ClinicalTrials.gov

Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B

PHASE3CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Chronic Viral Hepatitis B Without Delta-agent
Interventions
DRUG

Telbivudine

Telbivudine 600 mg Daily Oral

DRUG

Entecavir

Entecavir 0.5 mg Daily Oral

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER